MX2008016254A - Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia. - Google Patents
Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia.Info
- Publication number
- MX2008016254A MX2008016254A MX2008016254A MX2008016254A MX2008016254A MX 2008016254 A MX2008016254 A MX 2008016254A MX 2008016254 A MX2008016254 A MX 2008016254A MX 2008016254 A MX2008016254 A MX 2008016254A MX 2008016254 A MX2008016254 A MX 2008016254A
- Authority
- MX
- Mexico
- Prior art keywords
- ischemia
- coronary
- pharmaceutical composition
- hydroxymethyl
- dose
- Prior art date
Links
- 208000028867 ischemia Diseases 0.000 title claims abstract description 34
- 101150051188 Adora2a gene Proteins 0.000 title claims description 25
- 239000003379 purinergic P1 receptor agonist Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 42
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 241000124008 Mammalia Species 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 229940044601 receptor agonist Drugs 0.000 claims description 25
- 239000000018 receptor agonist Substances 0.000 claims description 25
- -1 Pyrazol-4-yl Chemical group 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 206010047139 Vasoconstriction Diseases 0.000 claims description 11
- 210000002216 heart Anatomy 0.000 claims description 11
- 230000025033 vasoconstriction Effects 0.000 claims description 11
- 230000010412 perfusion Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- SZQIRVBJFJWUEK-XWXWGSFUSA-N (2r,3r,4s,5r)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NN(CCCCC)C=C1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 SZQIRVBJFJWUEK-XWXWGSFUSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 229960003614 regadenoson Drugs 0.000 description 29
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 description 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 230000024883 vasodilation Effects 0.000 description 7
- 239000002465 adenosine A2a receptor agonist Substances 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 3
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940127600 A2A receptor antagonist Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81575506P | 2006-06-22 | 2006-06-22 | |
| PCT/US2007/071882 WO2008063712A1 (en) | 2006-06-22 | 2007-06-22 | Use of a2a adenosine receptor agonists in the treatment of ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008016254A true MX2008016254A (es) | 2009-01-15 |
Family
ID=38596382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008016254A MX2008016254A (es) | 2006-06-22 | 2007-06-22 | Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070299089A1 (https=) |
| EP (1) | EP2068850A1 (https=) |
| JP (2) | JP2009541354A (https=) |
| CA (1) | CA2655310A1 (https=) |
| MX (1) | MX2008016254A (https=) |
| WO (1) | WO2008063712A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| CA2671940A1 (en) | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| NZ537975A (en) * | 2002-07-29 | 2007-08-31 | Cv Therapeutics Inc | Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| KR20070083714A (ko) | 2004-10-20 | 2007-08-24 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ2ａ 아데노신 수용체 작용제의 용도 |
| US7732595B2 (en) | 2006-02-03 | 2010-06-08 | Gilead Palo Alto, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
| US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
| RU2459626C2 (ru) * | 2006-09-01 | 2012-08-27 | Гайлид Сайэнсиз, Инк. | Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| US20080170990A1 (en) * | 2006-09-29 | 2008-07-17 | Cv Therapeutics, Inc. | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease |
| JP2010515081A (ja) * | 2007-01-03 | 2010-05-06 | ギリアード・パロ・アルト・インコーポレイテッド | 心筋灌流画像化 |
| AU2009296235A1 (en) * | 2008-09-29 | 2010-04-01 | Gilead Sciences, Inc. | Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods |
| EP3506947A4 (en) * | 2016-09-01 | 2020-06-03 | Leiutis Pharmaceuticals Pvt. Ltd. | PHARMACEUTICAL FORMULATIONS OF REGADENOSONE |
| CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| CN112381780B (zh) * | 2020-11-11 | 2021-04-20 | 上海市第六人民医院 | 一种冠脉微循环状况评估装置及方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| JPS6299395A (ja) * | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | ２−アルキニルアデノシンおよび抗高血圧剤 |
| US4968697A (en) * | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
| DE3831430A1 (de) * | 1988-09-15 | 1990-03-22 | Bayer Ag | Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| EP0444196B1 (en) * | 1988-11-15 | 1994-06-08 | Yamasa Shoyu Kabushiki Kaisha | Agent for treatment and prophylaxis of ischemic disease of heart or brain |
| ES2077070T3 (es) * | 1989-06-20 | 1995-11-16 | Yamasa Shoyu Kk | Intermedio de sintesis de 2-alquiniladenosina, produccion de dicho intermedio, produccion de 2-alquiniladenosina a partir de dicho intermedio, y derivado de 2-alquiniladenosina estable. |
| US5032252A (en) * | 1990-04-27 | 1991-07-16 | Mobil Oil Corporation | Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator |
| US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
| JP2740362B2 (ja) * | 1991-02-12 | 1998-04-15 | ヤマサ醤油株式会社 | 安定な固体状２‐オクチニルアデノシンおよびその製造法 |
| IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| US5705491A (en) * | 1992-10-27 | 1998-01-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Adenosine deaminase inhibitor |
| US6514949B1 (en) * | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
| US6448235B1 (en) * | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| US5770716A (en) * | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
| US6026317A (en) * | 1998-02-06 | 2000-02-15 | Baylor College Of Medicine | Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists |
| CA2316994A1 (en) * | 1998-06-08 | 1999-12-16 | Epigenesis Pharmaceuticals, Inc. | Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
| US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6368573B1 (en) * | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6552023B2 (en) * | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| CA2671940A1 (en) * | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| US6670334B2 (en) * | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| US6995148B2 (en) * | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
| US6599283B1 (en) * | 2001-05-04 | 2003-07-29 | Cv Therapeutics, Inc. | Method of preventing reperfusion injury |
| BR0209386A (pt) * | 2001-05-14 | 2004-07-06 | Novartis Ag | Derivados de sulfonamida |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| NZ537975A (en) * | 2002-07-29 | 2007-08-31 | Cv Therapeutics Inc | Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| KR20070083714A (ko) * | 2004-10-20 | 2007-08-24 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ2ａ 아데노신 수용체 작용제의 용도 |
| CN101102717A (zh) * | 2005-01-12 | 2008-01-09 | 王者制药研究发展有限公司 | 在有哮喘或支气管痉挛病史的患者中检测心肌功能障碍的方法 |
| US7732595B2 (en) * | 2006-02-03 | 2010-06-08 | Gilead Palo Alto, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
| RU2459626C2 (ru) * | 2006-09-01 | 2012-08-27 | Гайлид Сайэнсиз, Инк. | Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда |
| US20080170990A1 (en) * | 2006-09-29 | 2008-07-17 | Cv Therapeutics, Inc. | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease |
| JP2010515081A (ja) * | 2007-01-03 | 2010-05-06 | ギリアード・パロ・アルト・インコーポレイテッド | 心筋灌流画像化 |
-
2007
- 2007-06-22 CA CA002655310A patent/CA2655310A1/en not_active Abandoned
- 2007-06-22 US US11/766,964 patent/US20070299089A1/en not_active Abandoned
- 2007-06-22 MX MX2008016254A patent/MX2008016254A/es not_active Application Discontinuation
- 2007-06-22 WO PCT/US2007/071882 patent/WO2008063712A1/en not_active Ceased
- 2007-06-22 EP EP07870996A patent/EP2068850A1/en not_active Withdrawn
- 2007-06-22 JP JP2009516747A patent/JP2009541354A/ja active Pending
-
2012
- 2012-10-15 JP JP2012228109A patent/JP2013010797A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2655310A1 (en) | 2008-05-29 |
| US20070299089A1 (en) | 2007-12-27 |
| EP2068850A1 (en) | 2009-06-17 |
| JP2013010797A (ja) | 2013-01-17 |
| JP2009541354A (ja) | 2009-11-26 |
| WO2008063712A1 (en) | 2008-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008016254A (es) | Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia. | |
| JP3836128B2 (ja) | プリン組成物および投与方法 | |
| US20040068005A1 (en) | Pharmaceutical combinations | |
| JP2000507954A (ja) | 心拍停止の処置のためのバソプレシン及びアドレナリン作用薬の組合せ | |
| EP1037621A1 (en) | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal | |
| EP0711134B1 (en) | Medicinal for protection from neurological damage | |
| PL199652B1 (pl) | Sposób wytwarzania stałych kompozycji farmaceutycznych | |
| Neely et al. | A1-adenosine receptor antagonists block endotoxin-induced lung injury | |
| AU2005295437B2 (en) | Use of A2A adenosine receptor agonists | |
| JP2001521502A (ja) | Ｃ型肝炎の治療へのアマンタジンの使用 | |
| JP2022530042A5 (https=) | ||
| JP2010510973A (ja) | 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用 | |
| KR20060004959A (ko) | 신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법 | |
| EP2106791A1 (en) | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation | |
| BRPI0610498A2 (pt) | uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar | |
| JP2957618B2 (ja) | アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物 | |
| Van Wezel et al. | Comparison of nitroglycerine, verapamil and nifedipine in the management of arterial pressure during coronary artery surgery | |
| JP2024534156A (ja) | Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ | |
| EP0695185B1 (en) | Use of adenosine for the manufacture of a medicament for the treatment of pulmonary inflammatory reactions | |
| JP2009531367A5 (https=) | ||
| JP2012512851A (ja) | セトロンを頬側経粘膜投与するための処方物（ｆｏｒｍｕｌａｔｉｏｎ） | |
| US20030109486A1 (en) | Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) | |
| CN113332437A (zh) | Sur1抑制剂与藏花酸或其可药用盐联合作为神经保护剂的用途 | |
| JP7752425B2 (ja) | ２，２，６，６－テトラメチル－１－ピペリジニルオキシルの揮発使用による細胞死抑制と組織保護 | |
| Dasta et al. | Vasopressor-resistant hypotension following a massive ingestion of theophylline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: GILEAD SCIENCES, INC. |
|
| HC | Change of company name or juridical status |
Owner name: GILEAD SCIENCES, INC. |
|
| GB | Transfer or rights |
Owner name: GILEAD SCIENCES, INC. |
|
| FA | Abandonment or withdrawal |